AUTHOR INDEX

(P = Proceedings)

ABADIAS, M. *see* SANCHEZ, J.
ABEL, C. *see* TAN, R. S. H.
ACEBI, D. *see* RIETBROCK, S.
ACUFF, T. E. *see* HE, G.-W.
ADEBAYO, G. I., GAFFNEY, P., BUGGY, D. & FEELY, J. Acute inhibitory effect of alcohol on sodium-lithium countertransport, 476P
AHRENSTEDT, Ö. *see* LENNERNÄS, H.
AL JARAD, N., HUI, K. P. & BARNES, N. Effects of a thromboxane receptor antagonist on prostaglandin D_2 and histamine induced bronchoconstriction in man, 97
AL-HAMDAN, Y. *see* HOOGKAMER, J. F. W.
AL-HAMDAN, Y. *see* KLEINBLOESEM, C.
ALABASTER, C. T. *see* WALKER, D. K.
ALARAYYID, N. A., COOPER, M., SMITH, C. C. T. & PRICHARD, B. N. C. *In vitro* effect of the α_1-adrenergic receptor blockers naftopidil and doxazosin on calcium mobilization in platelets, 472P
ALLEN, E. *see* GEORGIOU, P.
ALLEN, E. *see* PRATT, S. K.
ALLEN, M. E. *see* VANDENBURG, M. J.
ALLOTT, R. *see* PIRMOHAMED, M.
AMOURETTI, M. *see* DEMOTES-MAINARD, F.
ANDERER, P. *see* SALETU, B.
ANDERSEN, P. H. *see* KUBOTA, K.
ANDERSON, G. D., GIDAL, B. E., HENDRYX, R. J., AWAN, A. B., TEMKIN, N. R., WILENSKY, A. J. & WINN, H. R. Decreased plasma protein binding of valproate in patients with acute head trauma, 559
ANDERSSON, T. *see* BIRKETT, D. J.
ANDERSSON, T., MINERS, J. O., VERONESE, M. E. & BIRKETT, D. J. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism, 597
ANDREWS, H. *see* DURSUN, S. M.
ANGELI, M. T. *see* TREMOLI, E.
ARANKO, K. *see* BACKMAN, J. T.
ARBOUW, F. *see* VAN ROOIJ, J.
ARENDT, J. *see* SKENE, D. J.
ARMSTRONG, E. *see* SZABADI, E.
ARYA, D. K. *see* SZABADI, E.
ASHFORTH, E. I. L., PALMER, J. L., BYE, A. & BEDDING, A. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine, 389
ASHGAR, M. N. & FORD, G. A. Management of hypertension in the elderly: attitudes of general practitioners and hospital physicians, 486P
ASHTON, C. H. *see* HARRISON, R. W. S.
AUDET, P. R. *see* PUE, M. A.
AUSTIN, C. E. & FOREMAN, J. C. Acoustic rhinometry compared with posterior rhinomanometry in the measurement of histamine- and bradykinin-induced changes in nasal airway patency, 33
AWAN, A. B. *see* ANDERSON, G. D.

BABER, N. Conference report. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH), 401
BACK, D. J. *see* BARRY, M.
BACK, D. J. *see* VEAL, G. J.
BACK, D. J. *see* WILD, M. J.
BACKMAN, J. T., OLKKOLA, K. T., ARANKO, K., HIMBERG, J.-J. & NEUVONEN, P. J. Dose of midazolam should be reduced during diltiazem and verapamil treatments, 221
BAGHERI, H., PICAULT, P., SCHMITT, L., HOUIN, G., BERLAN, M. & MONTASTRUC, J. L. Pharmacokinetic study of yohombine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants, 93
BALDAIA, J. *see* PESTANA, M.
BAMMERT-ADAMS, J. A. *see* BEGG, E. J.
BANCHIERI, N. *see* BERTI, T.
BANKEN, L. *see* HOLFORD, N. H. G.
BANKS, D. *see* FEHER, M. D.
BANNWARTH, B. *see* DEMOTES-MAINARD, F.
BANO, F. *see* BERTI, T.
BAPNA, J. S., SHEWADE, D. G. & PRADHAN, S. C. Letter to the Editors. Training medical professionals on the concepts of essential drugs and rational drug use, 399
BARLOW, R. J. *see* TAN, R. S. H.
BARNES, N. *see* AL JARAD, N.
BARR, C. S. *see* CARGILL, R. I.
BARRY, M. *see* VEAL, G. J.
BARRY, M. *see* WILD, M. J.
BARRY, M., HOWE, J. L., BACK, D. J., SWART, A. M., BRECKENRIDGE, A. M., WELLER, I. V. D., BEECHING, N. & NYE, F. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity, 7
BARRY, M., HOWE, J. L., ORMESHER, S., BACK, D. J., BRECKENRIDGE, A. M., BERGIN, C., MULCAHY, F., BEECHING, N. & NYE, F. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome, 421
BARRY-KINSELLA, C., SHARMA, S. C., COTTELL, E. & HARRISON, R. F. Nafarelin in the treatment of minimal stage endometriosis, 122P
BARTLETT, A. *see* SANCHEZ, J.
BAUER, L. A., O'SULLIVAN, T., REISS, W. G., HORN, J. R., OPHEIM, K., STRANDNESS, D. E. & CARITHERS, R. L. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis, 375
BEDDING, A. *see* ASHFORTH, E. I. L.
BEECHING, N. *see* BARRY, M.
BEGG, E. J., ROBSON, R. A., IKRAM, H., RICHARDS, A. M., BAMMERT-ADAMS, J. A., OLSON, S. C., POSVAR, E. L., REECE, P. A. & SEDMAN, A. J. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure, 302
BEIER, H. *see* VAN GRIENSVEN, J. M. T.
BENJAMIN, N. *see* CHEESMAN, A. R.
BENNETT, P. A. *see* NOTARIANNI, L.
BERGIN, C. *see* BARRY, M.
BERGMANN, J.-F. *see* MALLAT, A.
BERINGER, T. R. O. *see* PASSMORE, A. P.
BERLAN M. *see* BAGHERI, H.
BERNDT, A., OERTEL, R., RICHTER, K., GRAMATTÉ, T. & KIRCH, W. Food enhances the oral availability of tiracizine a new antiarrhythmic agent by affecting its first-pass hepatic metabolism, 496P
BERTI, T., GAJON, R. M., GRION, A. M., PARI, B., BANO, F. & BANCHIERI, N. Age-related patterns of benzodiazepine use, cigarette smoking and alcohol consumption; an interview of the general population, 106P
BERTILSSON, L. *see* DAHL, M.-L.
BERTOLOTTI, M., FERRARI, A., VITALE, G., TRENTI, T., CARULLI, N. & STERNIERI, E. Plasma time-course of naltrexone and 6β-naltrexol after oral naltrexone administration in patients with liver cirrhosis, 109P
BIANCHETTI, G. *see* PATAT, A.
BILLON, N., GLOAGUEN, F., FUNCK-BRENTANO, C. & JAILLON, P. Clinical evaluation of pain during subcutaneous injections of low molecular weight heparins in healthy volunteers, 395

BIRD, H. *see* FEELY, M.
BIRKETT, D. J. *see* ANDERSSON, T.
BIRKETT, D. J., REE, D., ANDERSSON, T., GONZALEZ, F. J., MINERS, J. O. & VERONESE, M. E. *In vitro* proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase, 413
BLACKWELL, C. P. *see* JOHNSON, M. A.
BLAIN, P. G. *see* SCIBERRAS, D. G.
BLIGH, J. *see* WALLEY, T.
BOIKE, S. C. *see* PUE, M. A.
BOJKOWSKI, C. J. *see* SKENE, D. J.
BOLDT, J., KNOTHE, CH., SCHINDLER, F., STERTMANN, W. A. & HEMPELMANN, G. Isolated circulatory response to intravenous administration of the ACE inhibitor enalaprilat, 341
BONDESSON, U. *see* DAHL, M.-L.
BONDIOLOTTI, G. P. *see* PICOTTI, G. B.
BOOMSMA, F. *see* DAUL, A.
BORDERIES, P. *see* QUERA-SALVA, M. A.
BORLAND, W. *see* OLDROYD, K. G.
BOUDET, J. *see* QUERA-SALVA, M. A.
BOUSTEAD, C. *see* CHOLERTON, S. C.
BOWES, S. G. *see* KIROLLOS, C.
BOWES, S. G. *see* O'NEILL, C. J. A.
BOWES, S. G. *see* WELLER, C.
BOWMAN, R. T. *see* HE, G.-W.
BOYTER, A. C., DAVEY, P. G., HUDSON, S. A. & LIPWORTH, B. J. Evaluation of an antibiotic prescribing protocol in a hospital respiratory unit, 509P
BRACKLEY, K., SCIBERRAS, D., HYMAN-TAYLOR, P., MURPHY, G., TOMASKA, L., CAPRA, N. & RUBIN, P. Lack of effect of oxytocin infusion on basal and corticotrophin releasing hormone (CRH)-stimulated ACTH secretion in man, 507P
BRADLEY, J. D. *see* TRACY, T. S.
BRADSHAW, C. M. *see* SZABADI, E.
BRAITHWAITE, R. *see* KENDALL, M. J.
BRAMLEY, P. N. *see* CHRYSTYN, H.
BRATER, D. C. *see* RUDY, A. C.
BRATER, D. C. *see* TRACY, T. S.
BRECKENRIDGE, A. *see* WALLEY, T.
BRECKENRIDGE, A. M. *see* BARRY, M.
BRODDE, Q.-E. *see* DAUL, A.
BROOM, C. *see* PRATT, S. K.
BROWN, M. J. & DICKERSON, J. E. C. α-adrenoceptor blockade and Ca^{++} blockade: a new combination for the treatment of hypertension, 474P
BROWN, T. A. *see* FILER, C. W.
BRUGIER, S. *see* VANDENBURG, M. J.
BRUNE, K. *see* GEISSLINGER, G.
BRUNE, K. *see* PALLAPIES, D.
BRUNING, T. A., HENDRIKS, M. G. C., CHANG, P. C., KUYPERS, E. A. P. & VAN ZWIETEN, P. A. Cholinergic vasodilation in the forearm of normotensive humans, 483P
BUGGY, D. *see* ADEBAYO, G. I.
BULPITT, C. J. *see* TAN, R. S. H.
BURGGRAAF, J. *see* VAN GRIENSVEN, J. M. T.
BURGUL, R. *see* CHRYSTYN, H.
BURNS, N. *see* LI KAM WA, T. C.
BYE, A. *see* ASHFORTH, E. I. L.
BYGATE, E. *see* PRATT, S. K.
BYGATE, E. A. *see* FILER, C. W.

CABANIS, M. J. *see* ROSENZWEIG, P.
CALVERT, A. H. *see* WEDGE, S. R.
CAPRA, N. *see* BRACKLEY, K.
CARDILLO, C., MORES, N. & FOLLI, G. Effects of different doses of benazepril on stress testing blood pressure in hypertensive patients, 113P
CARGILL, R. I. & LIPWORTH, B. J. Pulmonary vasorelaxant activity of ANP and BNP in man, 475P
CARGILL, R. I., COUTIE, W. C., MCFARLANE, L. C. & LIPWORTH, B. J. Effect of ANP and BNP on the pressor and aldosterone responses to angiotension II, 487P
CARGILL, R. I., COUTIE, W. J. & LIPWORTH, B. J. The effects of angiotensin II on circulating levels of natriuretic peptides, 484P
CARGILL, R. I., SRUTHERS, A. D., COUTIE, W. J., BARR, C. S. & LIPWORTH, B. J. C-type natriuretic peptide in hypoxaemic cor pulmonale, 520P
CARITHERS, R. L. *see* BAUER, L. A.
CARROLL, K. *see* DONOVAN, A. J. G.
CARULLI, N. *see* BERTOLOTTI, M.
CASTLEDEN, M. *see* ROBINSON, T.
CATALANO, I. *see* TREMOLI, E.
CAZENEUVE, C., PONS, G., REY, E., TRELUYER, J.-M., CRESTEIL, T., THIROUX, G., D'ATHIS, P. & OLIVE, G. Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults, 405
CHADWICK, D. *see* PIRMOHAMED, M.
CHAN, F., MCLACHLAN, A. J., PEGG, M., MACKAY, A. D., COLE, R. B. & ROWLAND, M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin, 563
CHAN, P. *see* TSAI, S. K.
CHAN, R. *see* FEELY, J.
CHAN, R. *see* HEMERYCK, L.
CHAN, R. *see* MCGETTIGAN, P.
CHANG, P. C. *see* BRUNING, T. A.
CHANNER, K. S. Letter to the Editors. β-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity, 615
CHANNER, K. S., JAMES, M. A., MACCONNELL, T. & REES, J. R. β-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity, 53
CHAPMAN, D. *see* PRATT, S. K.
CHAPMAN, F. *see* WEDGE, S. R.
CHARLETT, A. *see* KIROLLOS, C.
CHARLETT, A. *see* O'NEILL, C. J. A.
CHEESMAN, A. R. & BENJAMIN, N. Lack of tolerance in forearm blood vessels in man to glyceryl trinitrate, 441
CHIBA, K., SAITOH, A., KOYAMA, E., TANI, M., HAYASHI, M. & ISHIZAKI, T. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two enzyme kinetic analysis of *N*-demethylation and 2-hydroxylation, 237
CHILTON, J. E. *see* MACONOCHIE, J. G.
CHOLERTON, S., MCCRACKEN, N. W., JOHNSTONE, E. C., BOUSTEAD, C., TABER, H. & IDLE, J. R. A population study of the metabolism of an oral dose of nicotine in non-tobacco users, 517P
CHRYSTYN, H. *see* CORLETT, S. A.
CHRYSTYN, H., WINTERS, C., BRAMLEY, P. N., WONG, V., BURGUL, R., LOSOWSKY, M. S. & YORK, P. Improved absorption from a gliclazide betacyclodextrin complex formulation, 111P
CHWATAL, K. *see* SALETU, B.
CLARKE, R. A. *see* NEWNHAM, D. M.
COBBE, S. M. *see* OLDROYD, K. G.
COCKSHOTT, I. *see* DONOVAN, A. J. G.
COHEN, A. F. *see* PIETERS, M. S. M.
COHEN, A. F. *see* VAN GRIENSVEN, J. M. T.
COHEN, A. F. *see* VAN ROOIJ, J.
COHEN, A. F. *see* VAN STEVENINCK, A. L.
COHEN, A. F. *see* WALLNOFER, A. E.
COKKINOS, D. *see* DETRY, J. M.
COLE, R. B. *see* CHAN, F.
COLLI, S. *see* TREMOLI, E.
COMPTON, C. *see* GEORGIOU, P.
CONDREN, L. *see* HEMERYCK, L.
CONGRAVE, G. S. *see* WALKER, D. K.
CONRADI, E. C. *see* WALLE, U. K.
COOPER, K. J. *see* DONOVAN, A. J. G.
COOPER, M. *see* ALARAYYID, N. A.
CORCORAN, O. M. *see* HYLAND, R.
CORINALDES, R. *see* SCARPIGNATO, C.
CORLETT, S. A., PARKER, D., SELBY, P. & CHRYSTYN, H. Disposition of ifosfamide enantiomers when given by a short or continuous infusion, 121P
CORRADI, C. *see* SCARPIGNATO, C.
COSTA, A. *see* SANCHEZ, J.
COSTELLO, J. F. *see* HOOD, P. P.
COTTELL, E. *see* BARRY-KINSELLA, C.
COURT, L. A. *see* PATAT, A.
COUTIE, W. C. *see* CARGILL, R. I.
COUTIE, W. J. *see* CARGILL, R. I.
COUTIE, W. J. *see* WHEELDON, N. M.
COX, A., FEHER, M. D., LEVY, A., MAYNE, P. D. & LANT, A. F. Short-term metabolic effects of tiboline in post-menopausal women with non-insulin-dependent diabetes mellitus, 570P
CRAWFORD, T. J., HENDERSON, L. & KENNARD, C. Neuroleptic effects on voluntary saccadic eye movements in psychiatric patients, 504P
CRAWFORD, V. L. S. *see* PASSMORE, A. P.
CRESTREIL, T. *see* CAZENEUVE, C.

CUTLER, M. *see* ODBER, J.

D'ATHIS, P. *see* CAZENEUVE, C.
DAGG, K. D. *see* LIPWORTH, B. J.
DAHL, M.-L., LLERENA, A., BONDESSON, U., LINDSTROM, L. & BERTILSSON, L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms, 71
DANHOF, M. *see* VAN STEVENINCK, A. L.
DARGIE, H. *see* DETRY, J. M.
DARGIE, H. J. *see* GODFREY, E. G.
DAUL, A., ELTER-SCHULZ, M., MAN IN'T VELD, A. J., BOOMSMA, F. & BRODDE, Q.-E. Dose-dependent separation of dopaminergic and adrenergic effects of dopamine and epinine in healthy volunteers, 477P
DAVY, P. G. *see* BOYTER, A. C.
DAVI, G. *see* TREMOLI, E.
DAY, R. O., GEISSLINGER, G., PAULL, P. & WILLIAMS, K. M. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers, 79
DELCHIER, J.-C. *see* MALLAT, A.
DELLA PASCHOA, O. E., KLINGER, I., JAKOB, K., TRENK, D., JÄHNCHEN, E., LUCKOW, V. & SANTOS, S. R. C. Prolongation of PQ-interval as a measure of therapeutic equivalence between two formulations containing diltiazem, 121P
DEMOTES-MAINARD, F., VINCON, G., LABAT, L., AMOURETTI, M., NECCIARI, J., KIEFFER, G. & BANNWARTH, B. Cefpuramide kinetics and plasma protein binding in cholestasis, 295
DEN HARTIGH, J. *see* PIETERS, M. S. M.
DENYER, L. H., KIRBY, S. M., OLSSON, P. & VENTRESCA, G. P. GR106642X, a non-chlorinated propellant for use in metered-dose inhalers: safety, tolerability and pharmacokinetics in healthy volunteers, 509P
DETRY, J. M., SELLIER, P., PENNAFORTE, S., COKKINOS, D., DARGIE, H. & MATHES, P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina, 279
DEVOY, M. A. B. *see* YOUNG, M. A.
DEWS, I. *see* VANDENBURG, M. J.
DHILLON, D. P. *see* NEWNHAM, D. M.
DHUMEAUX, D. *see* MALLAT, A.
DICKERSON, J. E. C. *see* BROWN, M. J.
DINGEMANSE, J. *see* GUENTERT, T. W.
DINGEMANSE, J. *see* HOLFORD, N. H. G.
DIXON, R. M., MEIRE, H. B., POSNER, J. & ROLAN, P. E. Evaluation of non-invasive techniques to assess vasoconstriction by methoxamine in healthy volunteers, 473P
DOBBS, R. J. *see* KIROLLOS, C.
DOBBS, R. J. *see* O'NEILL, C. J. A.
DOBBS, R. J. *see* WELLER, C.
DOBBS, S. M. *see* KIROLLOS, C.
DOBBS, S. M. *see* O'NEILL, C. J. A.
DOBBS, S. M. *see* WELLER, C.
DOBROCKY, P. *see* NOTARIANNI, L.
DOMINICZAK, M. *see* GODFREY, E. G.
DONALDSON, K. M., WRIGHT, D. M., MATHLENER, I. S. & HARRY, J. D. The effect of fluvoxamine at steady state on the pharmacokinetics of theophylline after a single dose in healthy male volunteers, 492P
DONNELLY, R. & MORRIS, A. D. Drugs and insulin resistance: clinical methods of evaluation and new pharmacological metabolism, 311
DONOVAN, A. J. G., WILLIAMS, A. J., MARSHALL, P. W., COCKSHOTT, I., COOPER, K. J., CARROLL, K., YATES, R. A. & TUERSLEY, M. D. Tolerance and pharmacokinetics of Zeneca ZD7288, a sino-atrial node modulator, in healthy volunteers, 521P
DOUTHIT, M. B. *see* HE, G.-W.
DOVER, S. *see* ODBER, J.
DRAKE, M. *see* SILKE, B.
DUBRUC, C. *see* PATAT, A.
DURSON, S. M., ANDREWS, H. & REVELEY, M. A. Computerized continuous assessment of abnormal involuntary movements in Huntington's disease: improvement by sulpiride, 503P
DUTREUIL, C. *see* MALLAT, A.

EDSTEIN, M. D., SHANKS, G. D., TEJA-ISAVADHARM, P., RIECKMANN, K. H. & WEBSTER, H. K. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers, 67
EDWARDS, C. *see* KAMALI, F.
EDWARDS, G. *see* NA BANGCHANG, K.
ELIGINI, S. *see* TREMOLI, E.
ELLIOTT, C. *see* SCIBERRAS, D. G.
ELLIOTT, H. L. *see* MARSHALL, S.
ELOUAERE BLANC, L. *see* MALLAT, A.
ELTER-SCHULZ, M. *see* DAUL, A.

FAGAN, T. C. *see* WALLE, U. K.
FAIRLESS, A. *see* PUE, M. A.
FAIRLESS, A. J. *see* PRATT, S. K.
FANCOURT, G. *see* ROBINSON, T.
FEELY, J. *see* ADEBAYO, G. I.
FEELY, J. *see* HALL, M.
FEELY, J. *see* HEMERYCK, L.
FEELY, J. *see* MCGETTIGAN, P.
FEELY, J., CHAN, R., MCMANUS, J. & O'SHEA, B. Prescribing in general hospital practice and the influence of hospitals, 514P
FEELY, M., LINDSAY, S., SWINN, R., WILLIAMS, G., BIRD, H. & PULLAR, T. An evaluation of therapeutic drug (metabolite) monitoring to study compliance with allopurinol for gout, 112P
FEHER, M. D. *see* COX, A.
FEHER, M. D., FOXTON, J., BANKS, D., LANT, A. F. & WRAY R. Long-term safety of fibrate-statin combination therapy in the treatment of hypercholesterolaemia, 511P
FELL, G. *see* GEORGIOU, P.
FERNER, R. E. *see* SCOTT, D. K.
FERRARA, S. D. *see* PALATINI, P.
FERRARI, A. *see* BERTOLOTTI, M.
FIGUEROA, N. L. *see* RUDY, A. C.
FILER, C. W., BROWN, T. A., BYGATE, E. A., FOWLES, S. E., PRINCE, W. T. & RAMJI, J. V. Metabolic and pharmacokinetic studies of sodium [^{14}C]-penciclovir following intravenous administration to healthy subjects, 491P
FIRKUSNY, L. & GLEITER, C. H. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine, 383
FLETCHER, A. E. *see* TAN, R. S. H.
FOLLI, G. *see* CARDILLO, C.
FORD, G. A. *see* ASHGAR, M. N.
FORD, G. A. *see* HUSSAIN, R. M.
FORD, J. M. *see* MAKELA, P. M.
FOREMAN, J. C. *see* AUSTIN, C. E.
FORGO, I. *see* HOOGKAMER, J. F. W.
FORGO, I. *see* KLEINBLOESEM, C.
FORT, S., LEWIS, M. J., LUSCOMBE, D. K. & JOHN, D. N. Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter, 460
FOSTER, R. W. *see* HASSAN, N. A. G. M.
FOWLER, G. *see* LYONS, D.
FOWLES, S. E. *see* FILER, C. W.
FOWLES, S. E. *see* PRATT, S. K.
FOXTON, J. *see* FEHER, M. D.
FRANCIS, P. W. J. *see* O'DONNELL, S. R.
FREED, M. I. *see* PUE, M. A.
FREESTONE, S. *see* LI KAM WA, T. C.
FREESTONE, S., GILL, M. M., LI KAM WA, T. C., LEE, M. R. & PATEL, K. R. The effect of the monoamine oxidase inhibitor phenelzine on the metabolism and natriuretic effect of γ-L-glutamyl-L-dopa in normal man, 115P
FRESQUET, A. *see* SANCHEZ, J.
FRIEDEL, I. *see* HUMMEL, T.
FRISK, M. *see* QUERA-SALVA, M. A.
FRISON, G. *see* PALATINI, P.
FUNCK-BRENTANO, C. *see* BILLON, N.

GABRIELSSON, S. *see* NYBERG, G.
GAFFNEY, P. *see* ADEBAYO, G. I.
GAJON, R. M. *see* BERTI, T.
GALLI, C. *see* TREMOLI, E.
GALLIMBERTI, L. *see* PALATINI, P.
GALVA, M. D. *see* PICOTTI, G. B.
GAMBLE, J. & GARTSIDE, I. B. Six, weekly strain gauge plethysmography (MSG) measurements of hydraulic conductance in the calves of young women on oral contraceptives, and age-matched men, 481P
GANDOLFI, M. A. *see* SCARPIGNATO, C.
GARIBALLA, S. *see* ROBINSON, T.
GARTSIDE, I. B. *see* GAMBLE, J.

GAZZARD, B. G. *see* NOORMOHAMED, F. H.
GEISSLINGER, G. *see* DAY, R. O.
GEISSLINGER, G. *see* KOBAL, G.
GEISSLINGER, G. *see* PALLAPIES, D.
GEISSLINGER, G., LOTSCH, J., MENZEL, S., KOBAL, G. & BRUNE, K. Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers, 392
GEORGIOU, P., PRINCE, P., SANGER, G. J., SAWARD, B., KUMAR, R., COMPTON, C., FELL, G. & ALLEN, E. Orocaecal and whole gut transit time in man is unaffected by the 5-HT_3 receptor antagonist BRL 46470A, 488P
GERLOFF, J. *see* VAN GRIENSVEN, J. M. T.
GERRARD, L., WHEELDON, N. M & MCDEVITT, D. G. Central effects of single doses of captopril and bendrofluazide, alone and in combination, 518P
GERRARD, L., WHEELDON, N. M. & MCDEVITT, D. G. Psychomotor effects of combined atenolol/chlorthalidone administration: interaction with alcohol, 517P
GESSA, G. L. *see* PALATINI, P.
GHOSH, S. K. & NEALE, M. G. The effect of physiological manoeuvres on the absorption of inhaled nedocromil sodium, 305
GIANFRANCESCHI, G. *see* TREMOLI, E.
GIBSON, B. *see* LENNARD, L.
GIBSON, G. J. *see* KENDALL, M. J.
GIDAL, B. E. *see* ANDERSON, G. D.
GILL, M. M. *see* FREESTONE, S.
GILMORE, D. H. *see* PASSMORE, A. P.
GILROY, J. *see* MOORE, U. J.
GLEITER, C. H. *see* FIRKUSNY, L.
GLOAGUEN, F. *see* BILLON, N.
GNANT, M. F. X. *see* MADER, R. M.
GODFREY, E. G., STEWART, J., DARGIE, H. J., REID, J. L., DOMINICZAK, M., HAMILTON, C. A. & MCMURRAY, J. Effects of ACE inhibitors on oxidation of human low density lipoprotein, 63
GOLDBERG, M. R. *see* SCIBERRAS, D. G.
GONZALEZ, F. J. *see* BIRKETT, D. J.
GRAM, L. F. *see* ROSHOLM, J.-U.
GRAMATTÉ, T. *see* BERNDT, A.
GRAMATTÉ, T. & RICHTER, K. Paracetamol absorption from different sites in the human small intestine, 609
GRANT, D. *see* PASSMORE, A. P.
GRAY, C. E. *see* OLDROYD, K. G.
GRAY, P. A., JONES, T. & PARK, G. R. Blood concentrations of dopexamine in patients during and after orthotopic liver transplantation, 89
GREEN, V. J. *see* PIRMOHAMED, M.
GREENE, P. K. *see* TRACY, T. S.
GRION, A. M. *see* BERTI, T.
GROOPMAN, J. D. *see* KINIRONS, M. T.
GROSS, A. S. *see* PRICHARD-DAVIES, R.
GROSSET, D. G. *see* MUIR, K. W.
GRUBER, M. *see* KOBAL, G.
GRUNBERGER, J. *see* SALETU, B.
GUENTERT, T. W. *see* HOLFORD, N. H. G.
GUENTERT, T. W., HOLFORD, N. H. G., PFEFEN, J. P. & DINGEMANSE, J. Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B, 545
GUERRA, L. *see* PESTANA, M.
GUMBRELL, L. *see* WEDGE, S. R.
GÜNZLER, W. A. *see* VAN GRIENSVEN, J. M. T.

HAEGELE, K. D. *see* HUEBERT, N. D.
HALE, K. A. *see* KENDALL, M. J.
HALL, M., MCCORMACK, P. & FEELY, J. The spontaneous reporting of adverse drug reactions by nurses, 512P
HALL, S. D. *see* RUDY, A. C.
HALL, S. T. *see* LYONS, D.
HALLAS, M. J. *see* ROSHOLM, J.-U.
HAMILTON, C. A. *see* GODFREY, E. G.
HANSEN, J. M. *see* OLSEN, N. V.
HARRIS, A. M. *see* PRATT, S. K.
HARRISON, J., HENDERSON, L. & KENNARD, C. Abnormal refractoriness in patients with Parkinson's disease after brief withdrawal of L-dopa therapy, 506P
HARRISON, R. F. *see* BARRY-KINSELLA, C.
HARRISON, R. W. S. & ASHTON, C. H. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin and placebo in healthy volunteers, 231
HARRY, J. D. *see* DONALDSON, K. M.
HARTIGAN-GO, K. *see* HUSSAIN, R. M.
HARVEY, K. *see* OLDROYD, K. G.
HASSAN, N. A. G. M. & FOSTER, R. W. Bronchodilator potency and effectiveness of two different formulations of inhaled SDZ MKS 492 assessed in normal human subjects, 120P
HASSAN, N. A. G. M., FOSTER, R. W. & JUBBER, A. S. Airway responsiveness to inhaled ipratropium in models of bronchospastic asthma created by inhaled histamine and methacholine in normal human subjects, 508P
HASSELGREN, B. *see* NYBERG, G.
HAYASHI, M. *see* CHIBA, K.
HAYBALL, P. J., WROBEL, J., TAMBLYN, J. G. & NATION, R. L. The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate, 75
HAYNES, W. G. & WEBB, D. J. Effects of intra-arterial administration of endothelin-1 and endothelin-3 on the forearm resistance bed of man, 472P
HE, G.-W., ACUFF, T. E., RYAN, W. H., YANG, C.-Q., DOUTHIT, M. B., BOWMAN, R. T. & MACK, M. J. Inhibitory effects of calcium antagonists on α-adrenoceptor-mediated contraction in the human internal mammary artery, 173
HEMERYCK, L., MCGETTIGAN, P., CHAN, R., MCCORMACK, P., CONDREN, L. & FEELY, J. An audit of pharmaceutical advertisements, 513P
HEMPELMANN, G. *see* BOLDT, J.
HENDERSON, L. *see* CRAWFORD, T. J.
HENDERSON, L. *see* HARRISON, J.
HENDRIKS, M. G. C. *see* BRUNING, T. A.
HENDRYX, R. J. *see* ANDERSON, G. D.
HERITY, N. *see* SILKE, B.
HERXHEIMER, A. Letter to the Editors. β-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity, 613
HIGENBOTTAM, T. *see* LOWRY, R.
HIGGS, C. J. *see* NOORMOHAMED, F. H.
HIMBERG, J.-J. *see* BACKMAN, J. T.
HINZE, C. *see* HUEBERT, N. D.
HOGLUND, P. *see* WESTERLING, D.
HOLDICH, T. *see* ROLAN, P. E.
HOLFORD N. H. G. *see* GUENTERT, T. W.
HOLFORD, N. H. G., GUENTERT, T. W., DINGEMANSE, J. & BANKEN, L. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor, 433
HOLFORD, N. H. G., GUENTERT, T. W., DINGEMANSE, J. & KETTLER, R. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monamine oxidase B, 553
HOLLANDER, A. A. M. J. *see* VAN ROOIJ, J.
HONG, C. Y. *see* TSAI, S. K.
HOOD, P. P., SAMPSON, A. P., COSTELLO, J. F. & PIPER, P. J. Peripheral blood neutrophils of atopic and asthmatic subjects are primed *in vivo* for enhanced leuokotriene B_4 generation, 477P
HOOGKAMER, J. F. W. *see* KLEINBLOESEM, C.
HOOGKAMER, J. F. W., AL-HAMDAN, Y., KLEINBLOESEM, C., FORGO, I., JOVIC, R., OUWERKERK, M. & SIERRA, J. R. Pharmacokinetics of D-norpseudo-ephedrine in healthy subjects employing GC-MS, 500P
HORN, J. R. *see* BAUER, L. A.
HOUIN, G. *see* BAGHERI, H.
HOWE, J. L. *see* BARRY, M.
HUDSON, S. A. *see* BOYTER, A. C.
HUEBERT, N. D., SCHWARTZ, J.-J., HINZE, C. & HAEGELE, K. D. Bioavailability and the effect of food on the pharmacokinetics of dolasetron mesylate and its active metabolite, MDL 74156, in man, 120P

HUI, K. P. *see* AL JARAD, N.
HUISMAN, L. G. M. *see* VAN GRIENSVEN, J. M. T.
HUMMEL, C. *see* HUMMEL, T.
HUMMEL, C. *see* KOBAL, G.
HUMMEL, T. *see* KOBAL, G.
HUMMEL, T., HUMMEL, C., FRIEDEL, I., PAULI, E. & KOBAL, G. A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline, 325
HUNT, W. B. *see* KIROLLOS, C.
HUSSAIN, A. *see* PASSMORE, A. P.
HUSSAIN, R. M., HARTIGAN-GO, K., THOMAS, S. H. L. & FORD, G. A. Effect of oxybutin on the QT-C interval in elderly patients with urinary incontinence, 485P.
HUTTINOT, G. *see* KUBOTA, K.
HYLAND, R., CORCORAN, O. M., JONES, B. C. & SMITH, D. A. Species differences in the *in vitro* metabolism of probe substrates for CYP2 enzymes, 489P
HYMAN-TAYLOR, P. *see* BRACKLEY, K.

IDLE, J. R. *see* CHOLERTON, S.
ILSON, B. *see* PUE, M. A.
IKRAM, H. *see* BEGG, E. J.
ISHIZAKI, T. *see* CHIBA, K.

JACKSON, S. H. D. Book review. Potassium channel modulators: pharmacological, molecular and clinical aspects, edited by A. H. Weston and T. C. Hamilton, 215
JACKSON, S. H. D. *see* KALRA, L.
JACKSON, S. H. D. *see* KINIRONS, M. T.
JAILLON, P. *see* BILLON, N.
JAKESZ, R. *see* MADER, R. M.
JAKOB, K. *see* DELLA PASCHOA, O. E.
JALAVA, M. *see* MATTILA, M. J.
JAMES, M. A. *see* CHANNER, K. S.
JÄHNCHEN, E. *see* DELLA PASCHOA, O. E.
JANSSON, K. A. *see* JONES, A. W.
JAYAKODY, R. L. *see* WEERASURIYA, K.
JEYASEELAN, K. *see* LEE, E. J. D.
JOHN, D. N. *see* FORT, S.
JOHNSON, M. A., BLACKWELL, C. P. & SMITH, J. Assessment of fluparoxan, an α_2-adrenoceptor antagonist, using intravenous clonidine, 490P
JOHNSTON, N. R. *see* LI KAM WA, T. C.
JOHNSTONE, E. C. *see* CHOLERTON, S.
JONES, A. W. & JANSSON, K. A. Between-subject and within-subject variations in the pharmacokinetics of ethanol, 427
JONES, B. C. *see* HYLAND, R.
JONES, B. C. *see* WALKER, D. K.
JONES, C. *see* PRATT, S. K.
JONES, T. *see* GRAY, D. A.
JORKASKY, D. K. *see* PUE, M. A.
JOVIC, R. *see* HOOGKAMER, J. F. W.
JUBBER, A. S. *see* HASSAN, N. A. G. M.

KAISER, R. R. *see* KLEINBLOESEM, C.
KALRA, L., SWIFT, C. G. & JACKSON, S. H. D. Psychomotor performance and antihypertensive treatment, 165
KAMALI, F. Influence of ciprofloxacin on ethanol pharmacokinetics and pharmacodynamics, 490P
KAMALI, F., NICHOLSON, E. & EDWARDS, C. Ciprofloxacin does not influence temazepam pharmacokinetics, 118P
KARBWANG, J. *see* NA BANGCHANG, K.
KASKI, J. C. *see* TIPPINS, J. R.
KEELEY, P. *see* MAKELA, P. M.
KEENE, O. N. *see* MACONOCHIE, J. G.
KENDALL, M. J., SPANNUTH, F., WALT, R. P., GIBSON, G. J., HALE, K. A., BRAITHWAITE, R. & LANGMAN, M. J. S. Lack of effect of H_2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime, 371
KENNARD, C. *see* CRAWFORD, T. J.
KENNARD, C. *see* HARRISON, J.
KETTLER, R. *see* HOLFORD, N. H. G.
KIEFFER, G. *see* DEMOTES-MAINARD, F.
KIIVET, R. A. *see* LLERENA, A.
KINIRONS, M. T., MASKREY, V., LAWSON, M., SWIFT, C. G. & JACKSON, S. H. D. Why does the Hawksley random zero sphygmomanometer under-record blood pressure?, 486P
KINIRONS, M. T., O'SHEA, D., GROOPMAN, J. D., THUMMEL, K. E., WOOD, A. J. J. & WILKINSON, G. R. Route of administration does not explain the lack of correlation between putative *in vivo* probes of cytochrome P4503A, 501P
KIRBY, S. M. *see* DENYER, L. H.
KIRCH, W. *see* BERNDT, A.
KIRCH, W. *see* OERTEL, R.
KIRCH, W. *see* TRAUSCH, B.
KIROLLOS, C., BOWES, S. G., CHARLETT, A., PURKISS, A., WELLER, C., O'NEILL, C. J. A., HUNT, W. B., DOBBS, S. M. & DOBBS, R. J. An evaluation, with objective assessment, of selegiline monotherapy in newly diagnosed elderly sufferers from idiopathic parkinsonism, 114
KITTERINGHAM, N. R. *see* PIRMOHAMED, M.
KIVIST, K. T. *see* LEHTO, P.
KLEINBLOESEM, C. *see* HOOGKAMER, J. F. W.
KLEINBLOESEM, C., AL-HAMDAN, Y., FORGO, I., OUWERKERK, M., PETERS, F., HOOGKAMER, J. F. W., KAISER, R. R. & SPITZNAGEL, W. Pharmacokinetics of ibuprofen after administration of a topical hydrogel formulation, 520P
KLINGER, I. *see* DELLA PASCHOA, O. E.
KLUFT, C. *see* VAN GRIENSVEN, J. M. T.
KNOTHE, CH. *see* BOLDT, J.
KOBAL, G. *see* GEISSLINGER, G.
KOBAL, G. *see* HUMMEL, T.
KOBAL, G., HUMMEL, C., GRUBER, M., GEISSLINGER, G. & HUMMEL, T. Dose-related effects of ibuprofen on pain-related potentials, 445
KOYAMA, E. *see* CHIBA, K.
KRISHNAIAH, Y. S. R., SATYANARAYANA, S. & VISWESWARAM, D. Interaction between tolbutamide and ketoconazole in healthy subjects, 205
KROON, J. M. *see* VAN GRIENSVEN, J. M. T.
KUBOTA, K., LO, E. S., HUTTINOT, G., ANDERSEN, P. H. & MAIBACH. H. I. Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration, 86
KUHN, S. *see* PRATT, S. K.
KUMAR, R. *see* GEORGIOU, P.
KUMAR, R. *see* PRATT, S. K.
KUYPERS, E. A. P. *see* BRUNING, T. A.

LABAT, L. *see* DEMOTES-MAINARD, F.
LAMB, R. J. *see* LIPTROT, J. L.
LAMB, R. J. *see* MERCER, A. J.
LANG-JENSEN, T. *see* OLSEN, N. V.
LANGLEY, R. W. *see* SZABADI, E.
LANGMAN, M. J. S. *see* KENDALL, M. J.
LANT, A. F. *see* COX, A.
LANT, A. F. *see* FEHER, M. D.
LANT, A. F. *see* NOORMOHAMED, F. H.
LAOHAVINIJ, S. *see* WEDGE, S. R.
LAROCHE, S. E. *see* PRATT, S. K.
LAWSON, M. *see* KINIRONS, M. T.
LE PETIT, G. *see* TRAUSCH, B.
LEATHAM, E. *see* TIPPINS, J. R.
LEE, E. J. D. & JEYASEELAN, K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population, 605
LEE, E. J. D. Population genetics of the angiotensin-converting enzyme in Chinese, 212
LEE, M. R. *see* FREESTONE, S.
LEE, M. R. *see* LI KAM WA, T. C.
LEE, T. Y. *see* TSAI, S. K.
LEES, K. R. *see* MUIR, K. W.
LEES, K. R. *see* SQUIRE, I. B.
LEHTO, P., KIVIST, K. T. & NEUVONEN, P. J. The effects of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin, 82
LENNARD, L., GIBSON, B., NICOLE, T. & LILLEYMAN, J. S. Dosage requirements for 6-mercaptopurine chemotherapy in the thiopurine methyltransferase deficient child, 111P
LENNARD, M. S. *see* WEERASURIYA, K.
LENNARD, M. S. *see* WILLIAMS, M. L.
LENNERNÄS, H., AHRENSTEDT, Ö. & UNGELL, A.-L. Intestinal drug absorption during induced net water absorption in man: a mechanistic study using antipyrine, atenolol and enalaprilat, 589
LEVY, A. *see* COX, A.
LEWIS, M. J. *see* FORT, S.
LEYSSAC, P. P. *see* OLSEN, N. V.
LI KAM WA, T. C. *see* FREESTONE, S.

LI KAM WA, T. C. *see* MCCRINDLE, J. L.
LI KAM WA, T. C., BURNS, N., WILLIAMS, B. C., FREESTONE, S. & LEE, M. R. Blood and urine 5-hydroxytryptophan and 5-HT levels after intravenous administration of two 5-HT prodrugs in normal man, 515P
LI KAM WA, T. C., FREESTONE, S., SAMSON, R. R., JOHNSTON, N. R. & LEE, M. R. Carbidopa prevents the increased urinary 5-HT excretion and the antinatriuresis following infusion of γ-L-5-hydroxy-L-tryptophan in normal man, 107P
LILLEYMAN, J. S. *see* LENNARD, L.
LINDSAY, S. *see* FEELY, M.
LINDSTROM, L. *see* DAHL, M.-L.
LINZMAYER, L. *see* SALETU, B.
LIPTROT, J. L., MERCER, A. J., LAMB, R. J. & POSNER, J. The effect of caffeine (200, 400 and 600 mg) on a battery of standard cognitive performance tests in healthy, caffeine withdrawn volunteers, 503P
LIPWORTH, B. J. & DAGG, K. D. Comparative effects of angiotensin II on Doppler parameters of left and right systolic and diastolic blood flow, 273
LIPWORTH, B. J. *see* BOYTER, A. C.
LIPWORTH, B. J. *see* CARGILL, R. I.
LIPWORTH, B. J. *see* NEWNHAM, D. M.
LIPWORTH, B. J. *see* WHEELDON, N. M.
LLERENA, A. & KIIVET, P. A. Fixed combination of neuroleptics with antidepressants: potential risks and estimation of use, 531
LLERENA, A. *see* DAHL, M.-L.
LO, E. S. *see* KUBOTA, K.
LOCKER, G. *see* MADER, R. M.
LOSOWSKY, M. S. *see* CHRYSTYN, H.
LOTSCH, J. *see* GEISSLINGER, G.
LOWRY, R., WOOD, A. & HIGENBOTTAM, T. The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections, 187
LUCKOW, V. *see* DELLA PASCHOA, O. E.
LUNDIN, S. *see* WESTERLING, D.
LUSCOMBE, D. K. *see* FORT, S.
LYONS, D., FOWLER, G., WEBSTER, J., HALL, S. T. & PETRIE, J. C. An assessment of lacidipine and atenolol in mild to moderate hypertension, 45
LYONS, D., WEBSTER, J., WEBSTER, J., FOWLER, G. & PETRIE, J. C. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia, 59

MACCONNELL, T. *see* CHANNER, K. S.
MACDONALD, T. M. *see* WHEELDON, N. M.
MACFADYEN, R. J. *see* SQUIRE, I. B.
MACK, M. J. *see* HE, G.-W.
MACKAY, A. D. *see* CHAN, F.
MACKAY, E. M. *see* VANDENBURG, M. J.
MACLEAN, D. *see* WHEELDON, N. M.
MACONOCHIE, J. G., MINTON, N. A., CHILTON, J. E. & KEENE, O. N. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?, 199
MADER, R. M., STEGER, G. G., RIZOVSKI, B., SIEDER, A. E., LOCKER, G., GNANT, M. F. X., JAKESZ, R. & RAINER, H. Pharmacokinetics of rac-leucovorin *vs* [S]-leucovorin in patients with advanced gastrointestinal cancer, 243
MADERNA, P. *see* TREMOLI, E.
MAIBACH, H. I. *see* KUBOTA, K.
MAKELA, P. M., TRUMAN C. A., FORD, J. M. & ROBERTS, C. J. C. Plasma protein binding characteristics of tacrine hydrochloride (THA), 489P
MAKELA, P. M., TRUMAN, C. A., FORD, J. M., KEELEY, P. & ROBERTS, C. J. C. What effect do ageing and disease have on the *in vitro* plasma protein binding of tacrine hydrochloride (THA)?, 117P
MALLAT, A., ROUDOT-THORAVAL, F., BERGMANN, J.-F., TROUT, H., SIMONNEAU, G., DUTREUIL, C., ELOUAERE BLANC, L., DHUMEAUX, D. & DELCHIER, J.-C. Inhibition of gastric alcohol dehydrogenase activity by histamine H_2-receptor antagonists has no influence on the pharmacokinetics of ethanol after a moderate dose, 208
MAN IN'T VELD, A. J. *see* DAUL, A.
MARANGONI, F. *see* TREMOLI, E.
MARSHALL, P. W. *see* DONOVAN, A. J. G.
MARSHALL, S., ELLIOTT, H. L. & MEREDITH, P. A. A population approach to dose *vs* response relationship for simvastatin in hypertensive hypercholesterolaemic patients, 494P
MARTIN, I. J. *see* WILLIAMS, M. L.
MARTIN, U. & PRESCOTT, L. F. The interaction of paracetamol with frusemide, 464
MASKREY, V. *see* KINIRONS, M. T.
MASOOD, A. R. *see* THOMAS, S. H. L.
MATHES, P. *see* DETRY, J. M.
MATHLENER, I. S. *see* DONALDSON, K. M.
MATTIE, H. *see* VERHAGEN, C. A.
MATTILA, M. J., JALAVA, M. & TARSSANEN, M. Does oral diazepam match ethanol in increasing postural sway?, 505P
MAYNE, P. D. *see* COX, A.
MCCANN, C. *see* QUERA-SALVA, M. A.
MCCARTHY, R. *see* PRATT, S. K.
MCCORMACK, P. *see* HALL, M.
MCCORMACK, P. *see* HEMERYCK, L.
MCCRACKEN, N. W. *see* CHOLERTON, S.
MCCRINDLE, J. L., LI KAM WA, T. C., NIMMO, W. S. & PRESCOTT, L. F. Influence of food on the absorption of frusemide and bumetanide in man, 478P
MCDEVITT, D. G. *see* GERRARD, L.
MCDEVITT, D. G. *see* NEWNHAM, D. M.
MCDEVITT, D. G. *see* WHEELDON, N. M.
MCELREA, M. S. *see* O'DONNELL, S. R.
MCFARLANE, L. C. *see* CARGILL, R. I.
MCGETTIGAN, P. *see* HEMERYCK, L.
MCGETTIGAN, P., CHAN, R., MCMANUS, J., O'SHEA, B. & FEELY, J. Sources of drug information in prescribing in general practice, 512P
MCHUGH, L. *see* O'NEILL, C. J. A.
MCKEE, P. J. W. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients, 27
MCLACHLAN, A. J. *see* CHAN, F.
MCMANUS, J. *see* FEELY, J.
MCMANUS, J. *see* MCGETTIGAN, P.
MCMURRAY, J. *see* GODFREY, E. G.
MEIRE, H. *see* ROLAN, P. E.
MEIRE, H. B. *see* DIXON, R. M.
MENZEL, S. *see* GEISSLINGER, G.
MERCER, A. J. *see* LIPTROT, J. L.
MERCER, A. J. *see* ROLAN, P. E.
MERCER, A. J., LAMB, R. J. & POSNER, J. The effect of lorazepam (1 mg) and caffeine (400 mg), alone and in combination, on the electro-encephalogram (EEG) of healthy, caffeine withdrawn volunteers, 502P
MEREDITH, P. A. *see* MARSHALL, S.
MERZ, P.-G. *see* RIETBROCK, S.
MEYER, PH. *see* QUERA-SALVA, M. A.
MINERS, J. O. *see* ANDERSSON, T.
MINERS, J. O. *see* BIRKETT, D. J.
MINTON, N. A. *see* MACONOCHIE, J. G.
MINTON, N. A. *see* YOUNG, M. A.
MINTON, N. A. Volunteer models for predicting antiemetic activity of 5-HT_3-receptor antagonists, 525
MONTASTRUC, J. L. *see* BAGHERI, H.
MONTGOMERY, A. *see* PASSMORE, A. P.
MOORE, K. *see* TIPPINS, J. R.
MOORE, M. R. *see* ODBER, J.
MOORE, U. J., SEYMOUR, R. A., GILROY, J. & RAWLINS, M. D. The efficacy of locally applied morphine in post-operative pain after third molar surgery, 227
MORES, N. *see* CARDILLO, C.
MORRIS, A. D. *see* DONNELLY, R.
MORSELLI, P. L. *see* PATAT, A.
MOTWANI, J. G. & STRUTHERS, A. D. Interactive effects of indomethacin, angiotensin II and frusemide on renal haemodynamics and natriuresis in man, 355
MUCKLOW, J. C. *see* PRATT, S. K.
MUIR, K. W., GROSSET, D. G. & LEES, K. R. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers, 522P

MULCAHY, F. *see* BARRY, M.
MURPHY, G. *see* BRACKLEY, K.

NA BANGCHANG, K., KARBWANG, J., THOMAS, C. G., THANAVIBUL, A., SUKONTASON, K., WARD, S. A. & EDWARDS, G. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria, 249
NATION, R. L. *see* HAYBALL, P. J.
NEALE, M. G. *see* GHOSH, S. K.
NECCIARI, J. *see* DEMOTES-MAINARD, F.
NEUVONEN, P. J. *see* BACKMAN, J. T.
NEUVONEN, P. J. *see* LEHTO, P.
NEWELL, D. R. *see* WEDGE, S. R.
NEWNHAM, D. M. *see* WHEELDON, N. N.
NEWNHAM, D. M., LIPWORTH, B. J., CLARK, R. A., WINTER, J. H., DHILLON, D. P. & MCDEVITT, D. G. Relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients, 476P
NICHOLL, C. G. *see* TAN, R. S. H.
NICHOLSON, E. *see* KAMALI, F.
NICOLE, T. *see* LENNARD, L.
NIMMO, W. S. *see* MCCRINDLE, J. L.
NOORMOHAMED, F. H. & LANT, A. F. Proximal renal tubular effects of loop diuretics, torasemide, bumetamide and frusemide, 478P
NOORMOHAMED, F. H., YOULE, M. S., HIGGS, C. J., GAZZARD, B. G. & LANT, A. F. Pharmacokinetics of intravenous foscarnet in AIDS patients: lack of effect of probenecid pretreatment, 519P
NOTARIANNI, L., DOBROCKY, P., BENNETT, P. A. & SILVERMAN, B. Caffeine as a probe for CYP1A2: a comparison of metabolic ratios, 480P
NYBERG, G., GABRIELSSON, S. & HASSELGREN, B. Effects of incremental doses of intravenous methylscopolamine on heart rate and blood pressure in young healthy men without and with steady-state β-adrenoceptor blockade, 113P
NYE, F. *see* BARRY, M.

O'DONNELL, S. R., MCELREA, M. S. & FRANCIS, P W. J. Sputum albumin in children during treatment for acute asthma, 108P
O'NEILL, C. J. A. *see* KIROLLOS, C.
O'NEILL, C. J. A. *see* WELLER, C.
O'NEILL, C. J. A., BOWES, S. G., CHARLETT, A., PURKISS, A. G., WELLER, C., DOBBS, S. M. & DOBBS, R. J. Siblings of elderly sufferers have a tendency towards idiopathic Parkinsonism: shared xenobiotic exposure or inheritance?, 505P
O'NEILL, C. J. A., CHARLETT, A., RICHARDSON, M. D., MCHUGH, L., BOWES, S. G., DOBBS, S. M., DOBBS, R. J. & WELLER, C. Seborrhoeic dermatitis in pre-clinical Parkinsonism: a xenobiotic influence in causation or simply an effect?, 115P
O'SHEA, B. *see* FEELY, J.
O'SHEA, B. *see* MCGETTIGAN, P.
O'SHEA, D. *see* KINIRONS, M. T.
O'SULLIVAN, T. *see* BAUER, L. A.
OAKEY, A. *see* WEDGE, S. R.
ODBER, J., CUTLER, M., DOVER, S. & MOORE, M. R. The effect of haem precursors on the binding of the peripheral benzodiazepine ligand [^{3}H]-PK11195 to human platelets, 498P
OERTEL, R. *see* BERNDT, A.
OERTEL, R., RICHTER, K. & KIRCH, W. Assay of talindol and its hydroxylated metabolites in urine by h.p.l.c. and GC/MS, 496P
OLDROYD, K. G., RANKIN, A. C., GRAY, C. E., HARVEY, K., BORLAND, W., RAE, A. P. & COBBE, S. M. Failure to reproduce the *in vitro* cardiac electrophysiological effects of naloxone in humans, 289
OLIVE, G. *see* CAZENEUVE, C.
OLKKOLA, K. T. *see* BACKMAN, J. T.
OLSEN, N. V., LANG-JENSEN, T., HANSEN, J. M., PLUM, I., THOMSEN, J. K., STRANDGAARD, S. & LEYSSAC, P. P. Effects of acute β-adrenoceptor blockade with metoprolol on the renal response to dopamine in normal humans, 347
OLSON, S. C. *see* BEGG, E. J.
OLSSON, P. *see* DENYER, L. H.
OPHEIM, K. *see* BAUER, L. A.
ORLANDO, R. *see* PALATINI, P.
ORME, M. *see* WALLEY, T.
ORMESHER, S. *see* BARRY, M.
OUWERKERK, M. *see* HOOGKAMER, J. F. W.
OUWERKERK, M. *see* KLEINBLOESEM, C.

PADRINI, R. *see* PALATINI, P.
PALATINI, P., TEDESCHI, L., FRISON, G., PADRINI, R., ZORDAN, R., ORLANDO, R., GALLIMBERTI, L., GESSA, G. L. & FERRARA, S. D. Dose-dependent absorption and elimination of γ-hydroxybutyric acid in healthy volunteers, 106P
PALLAPIES, D., PESKAR, B. A., BRUNE, K. & GESISSLINGER, G. Effects of platelet functions and pharmacokinetics of azaproprazone and ketorolac tromethamine given as single parenteral doses, 335
PALMER, A. J. *see* TAN, R. S. H.
PALMER, J. L. *see* ASHFORTH, E. I. L.
PARI, B. *see* BERTI, T.
PARK, B. K. *see* PIRMOHAMED, M.
PARK, G. R. *see* GRAY, P. A.
PARKER, D. *see* CORLETT, S. A.
PASSMORE, A. P., CRAWFORD, V. L. S., BERINGER, T. R. O., GILMORE, D. H., HUSSAIN, A., GRANT, D. & MONTGOMERY, A. Determinants of drug consumption in an elderly population in North and West Belfast, 119P
PATAT, A., PERRAULT, M. C., VANDEL, B., ULLICAC, N. & ZIELENIUK, I. Study on the pharmacodynamic interaction between mizolastine and lorazepam on psychomotor performance and memory in healthy volunteers, 118P
PATAT, A., TROCHERIE, S., THEBAULT, J. J., ROSENZWEIG, P., DUBRUC, C., BIANCHETTI, G., MORSELLI, P. L. & COURT, L. A. EEG profile of litoxetine after single and repeated administration in healthy volunteers, 157
PATEL, K. R. *see* FREESTONE, S.
PATERNICO, A. *see* SCARPIGNATO, C.
PAULI, E. *see* HUMMEL, T.
PAULL, P. *see* DAY, R. O.
PAZZUCCONI, F. *see* TREMOLI, E.
PECK, R. W. *see* ROLAN, P. E.
PEEBLES, L. *see* WHEELDON, N. M.
PEGG, M. *see* CHAN, F.
PENNAFORTE, S. *see* DETRY, J. M.
PERRAULT, M. C. *see* PATAT, A.
PESKAR, B. A. *see* PALLAPIES, D.
PESTANA, M., SAMEIRO, M., BALDAIA, J., GUERRA, L. & SOARES-DA-SILVA, P. Endogenous dopamine and the recovery of renal function in kidney transplant recipients, 479P
PETERS, F. *see* KLEINBLOESEM, C.
PETERS, J. A. *see* WHEELDON, N. M.
PETRIE, J. C. *see* LYONS, D.
PFEFEN, J. P. *see* GUENTERT, T. W.
PICAULT, P. *see* BAGHERI, H.
PICOTTI, G. B., SCIABA, L., VILLA, F., BONDIOLOTTI, G. P., REINA, G. & GALVA, M. D. Endogenous plasma levodopa increase as an index of peripheral dopa-decarboxylase inhibition by benserazide, 108P
PIETERS, M. S. M. *see* VAN STEVENINCK, A. L.
PIETERS, M. S. M., VAN STEVENINCK, A. L., SCHOEMAKER, R. C., DEN HARTIGH, J. & COHEN, A. F. The long term reproducibility of pharmacokinetics, pharmacodynamics and concentration-effect parameters of temazepam given intravenously in healthy volunteers, 500P
PIPER, P. J. *see* HOOD, P. P.
PIRMOHAMED, M., ALLOTT, R., GREEN, V. J., KITTERINGHAM, N. R., CHADWICK, D. & PARK, B. K. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy, 577
PITT, B. M. N. *see* TAN, R. S. H.
PLUM, I. *see* OLSEN, N. V.
POLI, G. *see* RIETBROCK, S.
PONS, G. *see* CAZENEUVE, C.
POSNER, J. *see* DIXON, R. M.
POSNER, J. *see* LIPTROT, J. L.
POSNER, J. *see* MERCER, A. J.
POSNER, J. *see* ROLAN, P. E.

POSVAR, E. L. *see* BEGG, E. J.
POTTER, J. *see* ROBINSON, T.
PRADHAN, S. C. *see* BAPNA, J. S.
PRASAD, N. *see* WHEELDON, N. M.
PRATT, S. K., FAIRLESS, A. J., PUE, M. A., HARRIS, A. M., MCCARTHY, R., CHAPMAN, D., BYGATE, E., BROOM, C., ALLEN, E., KUHN, S., JONES, C. & MUCKLOW, J. C. The pharmacokinetics of penciclovir in subjects with varying degrees of renal impairment, 493P
PRATT, S. K., PUE, M. A., FAIRLESS, A. J., FOWLES, S. E., LAROCHE, S. E., KUMAR, R. & PRINCE, W. T. Lack of an effect of gender on the pharmacokinetics of penciclovir following single oral doses of famciclovir, 493P
PRESCOTT, L. F. *see* MARTIN, U.
PRESCOTT, L. F. *see* MCCRINDLE, J. L.
PRICHARD, B. N. C. *see* ALARAYYID, N. A.
PRINCE, P. *see* GEORGIOU, P.
PRINCE, W. T. *see* FILER, C. W.
PRINCE, W. T. *see* PRATT, S. K.
PRITCHARD-DAVIES, R., GROSS, A. S. & SHENFIELD, G. M. The effect of liver disease and food on plasma MEGX concentrations, 298
PROCTOR, M. *see* WEDGE, S. R.
PUE, M. A. *see* PRATT, S. K.
PUE, M. A., BOIKE, S. C., FREED, M. I., AUDET, P. R., FAIRLESS, A., ILSON, B., ZARIFFA, N. & JORKASKY, D. K. Pharmacokinetics of penciclovir in subjects with hepatic insufficiency following oral famciclovir, 494P
PULLAN, T. *see* VANDENBURG, M. J.
PULLAR, T. *see* FEELY, M.
PURKISS, A. *see* KIROLLOS, C.
PURKISS, A. G. *see* O'NEILL, C. J. A.

QUERA-SALVA, M. A., MCCANN, C., BOUDET, J., FRISK, M., BORDERIES, P. & MEYER, PH. Effects of zolpidem on sleep architecture, night time ventilation, daytime vigilance and performance in heavy snorers, 539

RAE, A. P. *see* OLDROYD, K. G.
RAINER, H. *see* MADER, R. M.
RAMJI, J. V. *see* FILER, C. W.
RAMSAY, L. E. *see* WALLER, P. C.
RANKIN, A. C. *see* OLDROYD, K. G.
RAWLINS, M. D. *see* MOORE, U. J.
REDDY, S. *see* TAN, R. S. H.
REE, D. *see* BIRKETT, D. J.
REECE, P. A. *see* BEGG, E. J.
REED, J. E. *see* THOMAS, S. H. L.
REED, J. W. *see* SCIBERRAS, D. G.
REES, J. R. *see* CHANNER, K. S.
REID, J. L. *see* GODFREY, E. G.
REID, J. L. *see* SQUIRE, I. B.
REINA, G. *see* PICOTTI, G. B.
REISS, W. G. *see* BAUER, L. A.
REVELEY, M. A. *see* DURSUN, S. M.
REY, E. *see* CAZENEUVE, C.
RICHARDS, A. M. *see* BEGG, E. J.
RICHARDSON, M. D. *see* O'NEILL, C. J. A.
RICHTER, K. *see* BERNDT, A.
RICHTER, K. *see* GRAMATTÉ, T.
RICHTER, K. *see* OERTEL, R.
RIDOUT, G. *see* ROLAN, P. E.
RIECKMANN, K. H. *see* EDSTEIN, M. D.
RIETBROCK, S., ACEBI, D., POLI, G., MERZ, P.-G. & WOODCOCK, B. G. Comparison of the curve-fitting programs HOEREP-PC and TopFit using plasma concentration-time data for oral piroxicam-β-cyclodextrin and piroxicam formulations, 117P
RIZOVSKI, B. *see* MADER, R. M.
ROBERTS, C. J. C. *see* MAKELA, P. M.
ROBINSON, C. E. *see* YOUNG, M. A.
ROBINSON, T., GARIBALLA, S., FANCOURT, G., POTTER, J. & CASTLEDEN, M. The acute effects of a single dopamine infusion in elderly patients with congestive heart failure, 261
ROBSON, R. A. *see* BEGG, E. J.
ROLAN, P. E. Plasma protein binding displacement interactions—why are they still regarded as clinically important?, 125
ROLAN, P. E. *see* DIXON, R. M.
ROLAN, P. E., MERCER, A. J., WEATHERLEY, B. C., HOLDICH, T., MEIRE, H., PECK, R. W., RIDOUT, G. & POSNER, J. Examination of some factors responsible for a food-induced increase in absorption of atovaquone, 13
ROSENZWEIG, P. *see* PATAT, A.
ROSENZWEIG, P., ULLIAC, N. & CABANIS, M. J. Comparative wheal and flare study of mizolastine *vs* terfenadine, cetirizine, loratadine and placebo in healthy volunteers, 116P
ROSHOLM, J.-U., HALLAS, M. J. & GRAM, L. F. Concurrent use of more than one major pyschotropic drug (polypsychopharmacy) in out-patients—a prescription database study, 533
ROUDOT-THORAVAL, F. *see* MALLAT, A.
ROWLAND, M. *see* CHAN, F.
RUBIN, P. *see* BRACKLEY, K.
RUDY, A. C., FIGUEROA, N. L., HALL, S. D. & BRATER, D. C. The pharmacokinetics of piroxicam in elderly persons with and without renal impairment, 1
RYAN, W. H. *see* HE, G.-W.

SAITOH, A. *see* CHIBA, K.
SALETU, B., GRUNBERGER, J., LINZMAYER, L., SEMLITSCH, H. V., ANDERER, P. & CHWATAL, K. Pharmacokinetic and dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry, 145
SAMEIRO, M. *see* PESTANA, M.
SAMPSON, A. P. *see* HOOD, P. P.
SAMSON, R. R. *see* LI KAM WA, T. C.
SANCHEZ, J., COSTA, A., FRESQUET, A., ABADIAS, M. & BARTLETT, A. Letter to the Editors. HIV screening in 'healthy' volunteers and Ethics Committees, 469
SANGER, G. J. *see* GEORGIOU, P.
SANTOS, S. R. C. *see* DELLA PASCHOA, O. E.
SATYANARAYANA, S. *see* KRISHNAIAH, Y. S. R.
SAWARD, B. *see* GEORGIOU, P.
SCARPIGNATO, C., PATERNICO, A., GANDOLFI, M. A., STANGHELLINI, V., CORRADI, C. & CORINALDES, R. Pharmacological evaluation of human gastric emptying, 110P
SCHINDLER, F. *see* BOLDT, J.
SCHMITT, L. *see* BAGHERI, H.
SCHOEMAKER, H. C. *see* VAN GRIENSVEN, J. M. T.
SCHOEMAKER, H. C. *see* VAN ROOIJ, J.
SCHOEMAKER, R. C. *see* PIETERS, M. S. M.
SCHOEMAKER, R. C. *see* VAN STEVENINCK, A. L.
SCHWARTZ, J.-J. *see* HUEBERT, N. D.
SCIABA, L. *see* PICOTTI, G. B.
SCIBERRAS, D. *see* BRACKLEY, K.
SCIBERRAS, D. G., REED, J. W., ELLIOTT, C., BLAIN, P. G. & GOLDBERG, M. R. The effects of a peripherally selective α_2-adrenoceptor agonist, MK-467, on the metabolic and cardiovascular response to exercise in healthy man, 39
SCOTT, D. K. & FERNER, R. E. 'The strategy of desire' and rational prescribing, 217
SEDMAN, A. J. *see* BEGG, E. J.
SELBY, P. *see* CORLETT, S. A.
SELLIER, P. *see* DETRY, J. M.
SEMLITSCH, H. V. *see* SALETU, B.
SEYMOUR, R. A. *see* MOORE, U. J.
SHAH, D. *see* TIPPINS, J. R.
SHANKS, G. D. *see* EDSTEIN, M. D.
SHARMA, S. C. *see* BARRY-KINSELLA, C.
SHENFIELD, G. M. *see* PRITCHARD-DAVIES, R.
SHEWADE, D. G. *see* BAPNA, J. S.
SIEDER, A. E. *see* MADER, R. M.
SIERRA, J. R. *see* HOOGKAMER, J. F. W.
SILKE, B. & SPIERS, P. Exercise cardiac output actions of elgodipine assessed with the quantoscope, 483P
SILKE, B., SPIERS, P., HERITY, N. & DRAKE, M. Seismocardiography during therapeutic intervention, 481P
SILVERMAN, B. *see* NOTARIANNI, L.
SIMMONS, D. *see* WEDGE, S. R.
SIMONNEAU, G. *see* MALLAT, A.
SIRTORI, C. R. *see* TREMOLI, E.
SKENE, D. J., BOJKOWSKI, C. J. & ARENDT, J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans, 181

SMITH, C. A. D. *see* WEERASURIYA, K.
SMITH, C. C. T. *see* ALARAYYID, N. A.
SMITH, D. A. *see* HYLAND, R.
SMITH, D. A. *see* WALKER, D. K.
SMITH, J. *see* JOHNSON, M. A.
SMITH, N. K. G. *see* SZABADI, E.
SOARES-DA-SILVA, P. *see* PESTANA, M.
SPANNUTH, F. *see* KENDALL, M. J.
SPIERS, P. *see* SILKE, B.
SPITZNAGEL, W. *see* KLEINBLOESEM, C.
SQUIRE, I. B., MACFADYEN, R. J., LEES, K. R. & REID, J. L. First dose haemodynamic response to low dose quinapril in congestive heart failure, 516P
STANGHELLINI, V. *see* SCARPIGNATO, C.
STEGER, G. G. *see* MADER, R. M.
STERNIERI, E. *see* BERTOLOTTI, M.
STERTMANN, W. A. *see* BOLDT, J.
STEWART, J. *see* GODFREY, E. G.
STRANDGAARD, S. *see* OLSEN, N. V.
STRANDNESS, D. E. *see* BAUER, L. A.
STRUTHERS, A. D. *see* CARGILL, R. I.
STRUTHERS, A. D. *see* MOTWANI, J. G.
SUKONTASON, K. *see* NA BANGCHANG, K.
SVEDMAN, P. *see* WESTERLING, D.
SWART, A. M. *see* BARRY, M.
SWIFT, C. G. *see* KALRA, L.
SWIFT, C. G. *see* KINIRONS, M. T.
SWINN, R. *see* FEELY, M.
SZABADI, E., ARYA, D. K., LANGLEY, R. W., ARMSTRONG, E., SMITH, N. K. G. & BRADSHAW, C. M. Effects of amitriptyline on urine flow dynamics in healthy male volunteers, 507P

TABER, H. *see* CHOLERTON, S.
TAMBLYN, J. G. *see* HAYBALL, P. J.
TAN, R. S. H., BARLOW, R. J., ABEL, C., REDDY, S., PALMER, A. J., FLETCHER, A. E., NICHOLL, C. G., PITT, B. M. N. & BULPITT, C. J. The effect of low dose lofepramine in depressed elderly patients in general medical wards, 321
TARSSANEN, M. *see* MATTILA, M. J.
TAYLOR, G. A. *see* WEDGE, S. R.
TAYLOR, G. W. *see* TIPPINS, J. R.
TEDESCHI, L. *see* PALATINI, P.
TEJA-ISAVADHARM, P. *see* EDSTEIN, M. D.
TEMKIN, N. R. *see* EDSTEIN, M. D.
TEMKIN, N. R. *see* ANDERSON, G. D.
THANAVIBUL, A. *see* NA BANGCHANG, K.
THE VENOUS THROMBOEMBOLISM STUDY GROUP OF THE SPAN Multicentre hospital drug utilization study on the prophylaxis of venous thromboembolism, 255
THEBAULT, J. J. *see* PATAT, A.
THIROUX, G. *see* CAZENEUVE, C.
THOMAS, C. G. *see* NA BANGCHANG, K.
THOMAS, S. H. L. *see* HUSSAIN, R. M.
THOMAS, S. H. L., MASOOD, A. R. & REED, J. E. Lack of effect of nebulised morphine on breathlessness, ventilation and exercise endurance in patients with chronic obstructive pulmonary disease, 515P
THOMSEN, J. K. *see* OLSEN, N. V.
THUMMEL, K. E. *see* KINIRONS, M. T.
TIPLADY, B. The use of personal digital assistants in performance testing in psychopharmacology, 523P
TIPPINS, J. R., SHAH, D., LEATHAM, E., KASKI, J. C., MOORE, K. & TAYLOR, G. W. Coronary sinus leukotriene E_4 levels increase after percutaneous transluminal coronary angioplasty, 482P
TOMASKA, L. *see* BRACKLEY, K.
TOPMILLER, M. J. *see* WALLE, U. K.
TRACY, T. S., WORSTER, T., BRADLEY, J. D., GREENE, P. K. & BRATER, D. C. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis, 453
TRAUSCH, B., TRAUSCH, M., LE PETIT, G. & KIRCH, W. Disposition of dipyridamole, sulphamerazine and paracetamol in gastrectomized patients, 488P
TRAUSCH, M. *see* TRAUSCH, B.
TRELUYER, J.-M. *see* CAZENEUVE, C.
TREMOLI, E., MADERNA, P., MARANGONI, F., COLLI, S., ELIGINI, S., CATALANO, I., ANGELI, M. T., PAZZUCCONI, F., GIANFRANCESCHI, G., DAVI, G., SIRTORI, C. R. & GALLI, C. Assessment of the effects of n-fatty acid supplementation to healthy volunteers: dose, duration, and carry over of the treatment, 112P
TRENK, D. *see* DELLA PASCHOA, O. E.
TRENTI, T. *see* BERTOLOTTI, M.
TROCHERIE, S. *see* PATAT, A.
TROUT, H. *see* MALLAT, A.
TRUMAN, C. A. *see* MAKELA, P. M.
TSAI, S. K., CHAN, P., LEE, T. Y., YOUNG, J. M. & HONG, C. Y. Trilinolein improves erythrocyte deformability during cardiopulmonary bypass, 457
TUCKER, G. T. *see* WALLER, P. C.
TUCKER, G. T. *see* WEERASURIYA, K.
TUCKER, G. T. *see* WILLIAMS, M. L.
TUERSLEY, M. D. *see* DONOVAN, A. J. G.

ULLIAC, N. *see* PATAT, A.
ULLIAC, N. *see* ROSENZWEIG, P.
UNGELL, A. L. *see* LENNERNÄS, H.

VAN BREE, J. B. *see* VAN ROOIJ, J.
VAN DER WOUDE, F. J. *see* VAN ROOIJ, J.
VAN ES, L. A. *see* VAN ROOIJ, J.
VAN GRIENSVEN, J. M. T., BURGGRAAF, J., GERLOFF, J., GÜNZLER, W. A., BEIER, H., KROON, J. M., HUISMAN, L. G. M., SCHOEMAKER, H. C., KLUFT, C. & COHEN, A. F. The influence of changes in liver blood flow on the kinetics and dynamics of single chain urokinase-type plasminogen activator in healthy volunteers, 485P
VAN ROOIJ, J., HOLLANDER, A. A. M. J., ARBOUW, F., VAN BREE, J. B., SCHOEMAKER, H. C., VAN ES, L. A., VAN DER WOUDE, F. J. & COHEN, A. F. The effect of grapefruit juice on the pharmacokinetics of cyclosporine-A (CyA) in renal transplant patients, 497P
VAN STEVENINCK, A. L. *see* PIETERS, M. S. M.
VAN STEVENINCK, A. L., WALLNOFER, A. E., SCHOEMAKER, R. C., PIETERS, M. S. M., DANHOF, M. & COHEN, A. F. Sensitivity to benzodiazepines: influence of age and development of tolerance with chronic use of temazepam but not lorazepam, 497P
VAN STRIJEN, E. *see* VERHAGEN, C. A.
VAN ZWIETEN, P. A. *see* BRUNING, T. A.
VANDEL, B. *see* PATAT, A.
VANDENBURG, M. J. & ALLEN, M. E. Letter to the Editors. Good clinical practice—a question of balance, 101
VANDENBURG, M. J., MACKAY, E. M., DEWS, I., PULLAN, T. & BRUGIER, S. Dose finding studies with imidapril—a new ACE inhibitor, 265
VEAL, G. J. *see* WILD, M. J.
VEAL, G. J., WILD, M. J., BARRY, M. & BACK, D. J. Intracellular phosphorylation of zidovudine *in vitro*, 495P
VENTRESCA, G. P. *see* DENYER, L. H.
VERHAGEN, C. A., MATTIE, H. & VAN STRIJEN, E. The renal clearance of cefuroxime and ceftazidine and the effect of probenecid on their tubular excretion, 193
VERONESE, M. E. *see* ANDERSSON, T.
VERONESE, M. E. *see* BIRKETT, D. J.
VILLA, F. *see* PICOTTI, G. B.
VINCON, G. *see* DEMOTES-MAINARD, F.
VISWESWARAM, D. *see* KRISHNAIAH, Y. S. R.
VITALE, G. *see* BERTOLOTTI, M.

WALKER, D. K., ALABASTER, C. T., CONGRAVE, G. S., JONES, B. C. & SMITH, D. A. Formation, physical properties and pharmacological activity of the metabolites of dofetilide: *in vitro* studies, 499P
WALLE, T. *see* WALLE, U. K.
WALLE, U. K., FAGAN, T. C., TOPMILLER, M. J., CONRADI, E. C. & WALLE, T. The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers, 21
WALLER, P. C., TUCKER, G. T. & RAMSAY, L. E. Clinical pharmacology with confidence, 309
WALLEY, T., BLIGH, J., ORME, M. &

BRECKENRIDGE, A. Clinical pharmacology and therapeutics in undergraduate medical education in the UK: the future, 474P
WALLEY, T., BLIGH, J., ORME, M. & BRECKENRIDGE, A. Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status, 514P
WALLEY, T., BLIGH, J., ORME, M. & BRECKENRIDGE, A. I. Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status, 129
WALLEY, T., BLIGH, J., ORME, M. & BRECKENRIDGE, A. II. Clinical pharmacology and therapeutics in undergraduate medical education in the UK: the future, 137
WALLNOFER, A. E. & COHEN, A. F. Letter to the Editors. Good clinical practice—a question of balance, 101
WALLNOFER, A. E. *see* VAN STEVENINCK, A. L.
WALT, R. P. *see* KENDALL, M. J.
WARD, S. A. *see* NA BANGCHANG, K.
WEATHERLEY, B. C. *see* ROLAN, P. E.
WEBB, D. J. *see* HAYNES, W. G.
WEBSTER, H. K. *see* EDSTEIN, M. D.
WEBSTER, J. *see* LYONS, D.
WEDGE, S. R., LAOHAVINIJ, S., TAYLOR, G. A., NEWELL, D. R., PROCTOR, M., CHAPMAN, F., SIMMONS, D., OAKEY, A., GUMBRELL, L. & CALVERT, A. H. A phase I study of the antipurine antifolate lometrexol administered with an oral folic acid supplement, 498P
WEERASURIYA, K., JAYAKODY, R. L., LENNARD, M. S., TUCKER, G. T., SMITH, C. A. D. & WOLF, C. R. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study, 123P
WELLER, C. *see* KIROLLOS, C.
WELLER, C. *see* O'NEILL, C. J. A.
WELLER, C., O'NEILL, C. J. A., BOWES, S. G., DOBBS, R. J. & DOBBS, S. M. Towards objective outcome criteria in the elderly: gait on a shoestring, 123P
WELLER, I. V. D. *see* BARRY, M.
WESTERLING, D., HOGLUND, P., LUNDIN, S. & SVEDMAN, P. Transdermal administration of morphine to healthy subjects, 571
WHEELDON, N. M. *see* GERRARD, L.
WHEELDON, N. M., MCDEVITT, D. G. & LIPWORTH, B. J. Cardiac effects of the β_3-adrenoceptor agonist BRL35135 in man, 363
WHEELDON, N. M., MCDEVITT, D. G. & LIPWORTH, B. J. Effects of lower than conventional doses of oral nadolol on relative β_1/β_2-adrenoceptor blockade, 518P
WHEELDON, N. M., NEWNHAM, D. M., COUTIE, W. J., PETERS, J. A., MCDEVITT, D. G. & LIPWORTH, B. J. Influence of sex-steroid hormones on the regulation of lymphocyte β_2-adrenoceptors during the menstrual cycle, 583
WHEELDON, N. M., PRASAD, N., MACLEAN, D., PEEBLES, L., MCDEVITT, D. G. & MACDONALD, T. M. Bisoprolol and atenolol in essential hypertension: a double-blind comparative study of efficacy and patient acceptability, 521P
WILD, M. J. *see* VEAL, G. J.
WILD, M. J., VEAL, G. J., BARRY, M. & BACK, D. J. Intracellular phosphorylation of zidovudine *in vivo*, 480P
WILENSKY, A. J. *see* ANDERSON, G. D.
WILKINSON, G. R. *see* KINIRONS, M. T.
WILLIAMS, A. J. *see* DONOVAN, A. J. G.
WILLIAMS, B. C. *see* LI KAM WA, T. C.
WILLIAMS, G. *see* FEELY, M.
WILLIAMS, K. M. *see* DAY, R. O.
WILLIAMS, M. L., LENNARD, M. S., TUCKER, G. T. & MARTIN, I. J. The isomerization of 4-hydroxy-tamoxifen in human liver microsomes is mediated by cytochrome P450, 109P
WINN, H. R. *see* ANDERSON, G. D.
WINTER, J. H. *see* NEWNHAM, D. M.
WINTERS, C. *see* CHRYSTYN, H.
WOLF, C. R. *see* WEERASURIYA, K.
WONG, V. *see* CHRYSTYN, H.
WOOD, A. *see* LOWRY, R.
WOOD, A. J. J. *see* KINIRONS, M. T.
WOODCOCK, B. G. *see* RIETBROCK, S.
WORSTER, T. *see* TRACY, T. S.
WRAY, R. *see* FEHER, M. D.
WRIGHT, D. M. *see* DONALDSON, K. M.
WROBEL, J. *see* HAYBALL, P. J.

YANG, C.-Q. *see* HE, G.-W.
YATES, R. A. *see* DONOVAN, A. J. G.
YORK, P. *see* CHRYSTYN, H.
YOULE, M. S. *see* NOORMOHAMED, F. H.
YOUNG, M. A., ROBINSON, C. E., DEVOY, M. A. B. & MINTON, N. A. The influence of food on the pharmacokinetics of GR92132X, a thiazolidinedione, in healthy subjects, 482P
YUNG, J. M. *see* TSAI, S. K.

ZARIFFA, N. *see* PUE, M. A.
ZIELENIUK, I. *see* PATAT, A.
ZORDAN, R. *see* PALATINI, P.

SUBJECT INDEX

This index was compiled from the keywords

(P = Proceedings)

α-adrenoceptor blockade, 474P
α-adrenoceptors, 173
α_1-adrenergic receptor blocker, 472P
α_2-adrenoceptor antagonist, 93, 490P
ACE, 212
ACE inhibition, 265
ACE inhibitors, 63
AIDS patients, 519P
ANOVA, 427
Absorption, 13, 82, 106P, 111P, 478, 589, 608
Acoustic rhinometry, 33
Adverse drug reactions, 512P
Advertising, 217
Age, 1, 106P, 497P
Ageing, 117P, 261
Albumin, 108P
Alcohol, 106P, 371, 427, 476P, 517P
Aldosterone, 487P
Allopurinol, 112P
Amitriptyline, 507P
Analgesia, 227, 325
Angina pectoris, 279
Angiotensin II, 273, 355, 484P, 487P
Angiotensin converting enzyme, 212
Antiarrhythmic, 460
Antiarrhythmic drug, 496P, 499P
Antibiotic prescribing, 509P
Anticholinergic, 187
Antidepressant, 157
Antidepressants, 531
Antiepileptic drug, 27
Antinatriuresis, 107P
Antipyrine, 375, 589
Anxiolytic, 145
Artemether, 249
Arterioles, 441
Asthma, 108P, 476P, 477P, 508P
Atenolol, 45, 53, 517P, 521P, 589
Atovaquone, 13
Atrial fibrillation, 53, 613
Atrial fibrillation and flutter, 460
Atrial natriuretic peptide, 475P, 487P
Azapropazone, 335

β-adrenoceptor antagonist, 496P
β-adrenoceptor blockers, 53, 613
β_1/β_2-adrenoceptor blockade, 518P
β_2-adrenoceptor, 583
β_2-adrenoceptor antagonist, 199
β_3-adrenoceptor, 363
β-endorphin, 289
BRL 46470A, 488P
Benazepril, 113P
Bendrofluazide, 518P
Benserazide, 108P
Benzodiazepine use, 106P
Benzodiazepines, 497P
Betamethasone, 86
Betamethasone 17-valerate, 86
Bioavailability, 120P, 496P, 571
Bisoprolol, 521P
Blood concentrations, 89
Blood pressure, 486P
Blood pressure control, 24 h, 265
Bone marrow toxicity, 7
Book review, 103, 215
Bradykinin, 33
Brain natriuretic peptide, 475P, 487P
Bronchodilator, 187
Bumetanide, 478P

CNS 1102, 522P
CYP isoforms, 413, 597
CYP1A2, 480P
CYP2 enzymes, 489P
CYP2C subfamily, 237
CYP2D6, 383, 389, 605
CYP3A, 577
Caffeine, 405, 480P, 502P, 503P
Calcium, 472P
Calcium antagonist, 45, 483P
Calcium blockade, 474P
Captopril, 63, 518P
Carbamazepine, 577
Carbidopa, 107P
Cardiac electrophysiology, 289
Cardiac output, 483P
Cardiopulmonary bypass, 341, 457
Cefpiramide, 295
Ceftazidime, 193
Cefuroxime, 193
Central effects, 518P
Cephalosporin, 295
Cetirizine, 116P
Chemical stimulation, 325
Chemo-somatosensory event-related potential, 445
Chinese, 212
Chinese cytochrome P450, 605
Chlorthalidone, 517P
Cholecystokinin, 13
Cholestasis, 295
Cholesterol, 63, 231
Cholinergic vasodilation, 483P
Chronic obstructive pulmonary disease, 515P
Chronotropic response, 363
Cigarette smoking, 106P
Cimetidine, 79, 371
Ciprofloxacin, 82, 118P, 490P
Circulatory effects, 341
Cirrhosis, 109, 375
Clearance, 89, 193
Clinical pharmacology, 129, 137, 157, 474P, 514P
Clonidine, 490P
Clozapine, 71
Cognitive performance tests, 503P
Colestipol, 59
Compliance, 112P
Computerised continuous assessment, 503P
Confidence intervals, 309
Congestive cardiac failure, 261, 302, 516P
Cor pulmonale, 520P
Coronary angioplasty, 482P
Coronary bypass, 173
Corticosteroid, 86
Corticotrophin releasing hormone, 507P
Cortisol, 181
Cough, 187
Countertransport, 476P
Cycloguanil, 413
Cyclosporine A, 497P
Cytochrome P450, 109P, 237
Cytochrome P4503A, 501

D-glucose, 589
D-pseudoephedrine, 500P
Dapsone, 67
Debrisoquine, 71, 122P, 383P
Depression, 231, 321
Desipramine, 181
Diastereoisomers, 243
Diastolic blood flow, 273
Diazepam, 505P
Dideoxyinosine, 421
Dihydroartemisinin, 249
3,4-dihydroxyphenylglycol, 433
Diltiazem, 121P, 221
Dipyridamole, 488P
Disposition, 453
Diuresis, 464
Diuretics, 478P
Dofetilide, 499P
Dolasetron mesylate, 120P
DOPA decarboxylase, 108P
Dopamine, 261, 347, 477P, 479P
Dopexamine, 89
Doppler parameters, 273
Dosage, 59
Dose-finding, 265
Doxazosin, 472P
Drug consumption, 119P
Drug information, 512P
Drug interaction, 27, 75, 221
Drug utilization, 531

ECG, 157, 199, 231, 325, 445, 502P
EEG mapping, 145
Effective renal plasma flow, 261, 347
Elderly, 119P, 123P, 321, 486
Elgodipine, 483P
Elimination, 106P
Emesis, 525
Enalaprilat, 341, 589
Enantiomers, 21, 75, 121P, 392
Endometriosis, 122P
Endothelin 1, 472P
Endothelin 3, 472P
Enzyme induction, 577
Epilepsy, 27
Epinine, 477P

Erythrocyte deformability, 457
Essential drug use, 399
Essential hypertension, 265
Ethanol, 208, 490P, 505P
Ethanol gastric first pass metabolism, 208
Ethics committees, 469
Ethinyloestradiol, 21
Event-related potential, 325
Exercise testing, 279

Famciclovir, 493P, 494P
Famotidine, 371
n-3 fatty acids, 112P
Fenoterol, 476P
Ferrous sulphate, 82
Fibrate-statin combination, 511P
First pass hepatic metabolism, 496P
566C80, 13
Flare, 525
Fluparoxan, 490P
Flurbiprofen, 392
Fluvoxamine, 181, 492P
Folic acid, 498P
Food, 13, 120P, 298, 478P, 482P, 496P
Forearm, 441
Forearm resistance, 472P
Formation clearance, 375
Formulation, 120P
Foscarnet, 519P
Frusemide, 355, 464, 478P

γ-hydroxybutyric acid, 106P
γ-L-glutamyl–L-dopa, 115P
GR106642X, 509P
GR92132X, 482P
Gait, 123P
Gastrectomy, 488P
Gastric alcohol dehydrogenase, 208
Gastric emptying, 110P
Gastrointestinal cancer, 243
Gender, 21, 493P
General practice, 512P, 514P
General practitioners, 486P
Genetic polymorphism, 123P, 212, 605
Glicazide betacyclodextrin complex, 111P
Gliclazide, 111P
Glomerular filtration rate, 261, 347
Glyceryl trinitrate, 441
Good clinical practice, 101
Gout, 112P
Grapefruit juice, 497P

H.p.l.c., 242
H_2-receptor antagonists, 208
HIV infection, 480P
HIV screening, 469
HIV virus, 495P
HOEREP-PC, 117P
Hawksley random zero sphygmomanometer, 486P
Head trauma, 559
Heparin, 255
Heparin, low molecular weight, 255
Hepatic insufficiency, 494P
Hepatitis, 375
Histamine, 33, 508P
Histamine-induced bronchoconstriction, 383
Holter monitoring, 279
Hospital physicians, 486P
Hospital respiratory unit, 509P
5-HT prodrugs, 515P
5-HT_3 receptor antagonist, 488P
5-HT_3-receptor antagonists, 525
Human, 33, 97, 405
Human liver microsomes, 237
Human microsomal metabolism, 413, 597
Human psychopharmacology, 145
Humans, 21, 383
Huntington's disease, 503P
Hydrogel formulation, 520P
5-hydroxy-indoleactic acid, 433
2-hydroxylation, 237
4-hydroxytamoxifen, 109P
5-hydroxytryptamine, 107P
5-hydroxytryptophan, 515P
Hypercholesterolaemia, 59, 494P, 511P
Hypertension, 45, 113P, 165, 474P, 486P, 494P, 521P
Hypnotic, 539
Hypoalbuminaemia, 559

Ibuprofen, 445, 520P
Ifosfamide, 121P
Imipramine, 237, 325
In vivo probes, 501P
Indomethacin, 355
Inheritance, 505P
Inotropic response, 363
Insulin, 39
Insulin resistance, 311
Interaction, 45, 118P, 125, 205, 371, 453, 517P
Interactions, 82, 533
Internal mammary artery, 173
International conference on harmonisation, 401
Intestinal perfusion, 589, 608
Involuntary movements, 503P
Ipecacuanha, 525
Ipratropium, 508P
Isomerisation, 109P

Ketoconazole, 205
Ketorolac, 75, 335
(L)-ketorolac, 75
(R)-ketorolac, 75
Kidney transplant, 479P
Kinetics, 597

Labazemide, 545, 551
Lacidipine, 45
Laser Doppler flowmetry, 341
Leucovorin, 243
Leukotriene B_4, 477P
Leukotriene E_4, 482P
Levodopa, 108P, 506P
Lignocaine, 298
Lipolysis, 39
Lithium clearance, 347
Litoxetine, 157
Liver, 89
Liver blood flow, 375, 485P
Liver function, 298
Lofepramine, 321
Lometrexol, 498P
Loratadine, 116P
Lorazepam, 118P, 497P, 502P
Low density lipoprotein, 59, 63
Low molecular weight heparin, 395
Lymphocyte, 583

MAO inhibition, 433, 545, 551
Malaria, 67, 249
Man, 441
Maprotiline, 383
Maturation, 405
Medicines, 217
Melatonin, 181
Menstrual cycle, 21, 583
Mephenytoin, 123P
S-mephenytoin, 71
S-mephenytoin 4'-hydroxylase, 237
6-mercaptopurine, 111P
Metabolic, 199
Metabolic ratios, 480P, 491P
Metabolism, 405
Metabolites, 571
Metered dose inhaler, 509P
Methacholine, 508P
Methotrexate, 453
Methoxamine, 473P
Methylscopolamine, 113P
Metoprolol, 347
Microcirculation, 341
Microsomal epoxide hydrolase, 577
Microsomes, 405
Midazolam, 221
Miglyol, 13
Mizolastine, 116P, 118P
Moclobamide, 433
Modelling, 433, 545, 551
Monoamine metabolites, 433
Monoamine oxidase inhibitor, 115P
Monoethylglycinexylidide, 298
Morphine, 227, 515P, 571

N-acetylcysteine, 63
N-demethylation, 237
Nadolol, 363, 518P
Nafarelin, 122P
Naftopidil, 472P
Naloxone, 289
Naltrexone, 109P
Nasal airway, 33
Natriuresis, 464
Natriuretic peptide, 520P
Natriuretic peptides, 484P
Nedocromil sodium, 305
Net water absorption, 589
Neuroleptic effects, 504P
Neuroleptics, 531
Nicotine, 517P
Nifedipine, 173
Nitrate tolerance, 441
Nociception, 325, 445
Nocturnal ventilation, 539
Non-analgesic effects, 571
Non-competitive NMDA antagonist, 522P
Non-insulin-dependent diabetes, 510P
Non-invasive techniques, 473P
Non-steroidal anti-inflammatory drugs, 453
Noopsyche, 145
Noradrenaline, 39

Norfloxacin, 82
Normotensive, 483P

Oestradiol, 21, 583
Ofloxacin, 82
Omeprazole, 597
Ondansetron, 389
Oral contraceptives, 481P
Orocaecal transit time, 488P
Oxcarbazepine, 27
Oxidation, 63
Oxidised low density lipoprotein, 63
Oxybutynin, 485P
Oxytocin, 507P

PGD_2- and histamine induced bronchoconstriction, 97
PQ-interval, 121P
Pain, 325, 395, 445
Paracetamol, 464, 488P, 608, 488
Parkinson's disease, 506P
Parkinsonism, 114P, 505P
Partial agonist activity, 53, 613
Penciclovir, 491P, 493P, 494P
Percutaneous absorption, 86
Performance testing, 523P
Performance tests, 539
Peripheral action, 227
Permeability, 589
Personal digital assistants, 523P
Pharmaceutical advertisements, 513P
Pharmacodynamics, 45, 118P, 145, 433, 490P, 500P
Pharmacogenetics, 237, 531
Pharmacokinetics, 1, 7, 27, 45, 71, 79, 86, 118P, 120P, 145, 173, 208, 221, 243, 249, 295, 302, 305, 335, 389, 382, 421, 427, 460, 484P, 490P, 491P, 492P, 493P, 494P, 497P, 500P, 509P, 519P, 520P, 521P, 563
Phase 1 study, 498P
Phenelzine, 115P
Physiological manoeuvres, 305
Pindolol, 53
Piroxicam, 1
Plasma binding, 21
Plasma catecholamines, 93
Platelet aggregation, 335
Platelets, 472P, 551
Plethysmography, 441
Polymorphism, 67, 71
Polypsychopharmacy, 533
Population pharmacodynamics, 551
Population pharmacokinetics, 545
Population study, 517P
Post-menopausal women, 510P
Posterior rhinomanometry, 33
Postural sway, 505P
Pravastatin, 231
Prescribing, 217, 512P, 514P
Prescription database, 533
Probe substrates, 489P
Probenecid, 79, 193, 519P
Progesterone, 583
Proguanil, 67, 413
Propellant, non chlorinated, 509P
Propranolol, 21, 279
Prostaglandins, 464
Protein binding, 1, 117P, 125, 295, 489P, 559
Proximal renal tube, 478P
Psychiatric patients, 504P
Psychometry, 145
Psychomotor performance, 118P, 165
Psychopharmacology, 523P
Psychophysiology, 145
Psychotropic drugstropic, 533
Pulmonary embolism, prevention, 255

QTc interval, 485P
Quantascope, 483P
Quinapril, 63, 302, 516P
Quinaprilat, 63, 302

Ranitidine, 371
Rational drug use, 399
Registration of pharmaceuticals, 401
Renal function, 479P
Renal haemodynamics, 355
Renal impairment, 1
Renal transplantation, 497P
Renin, 464
Reproducibility, 427
Ro 19-6327, 545, 551

SDZ MKS 492, 120P
SSRI psychopharmacology, 157
Saccadic eye movements, 504P
Safety, 511P
Salbutamol, 476P
Salivary secretion, 93
Salmeterol, 199
Seborrhoeic dermatitis, 115P
Seismocardiography, 481P
Selegiline, 114P
Serotonin reuptake inhibitor, 157
Simvastatin, 231, 494P
Single chain urokinase plasminogen activator, 485P
Sino-atrial node modulator, 521P
Sleep, 539
Small intestine, 608
Snorer, 539
Sodium clearance, 347
Solvent drag, 589
Spontaneous reporting, 512P
Statistics, 309
Stereoisomers, 392
Strain gauge plethysmography, 481P
Sublingual, 460
Sulphamerazine, 488P
6-sulphatoxymelatonin, 181
Sulphydryl group, 63
Sulpiride, 503P
Surgery, 255
Suriclone, 145
Sympathomimetic amines, 173
Systolic blood flow, 273

Tachyphylaxis, 199
Tacrine hydrochloride, 117P, 489P
Talinolol, 496P
Temazepam, 118P, 497, 500P
Temozolomide, 480P
Tenoxicam, 79
Terfenadine, 116P
Testosterone, 21
Theophylline, 492P
Therapeutic drug metabolite monitoring, 112P
Therapeutics, 129, 137, 474P, 514P
Thiazolidinedione, 482P
Thiol, 63
Thiopurine methyltransferase, 111P
Thromboembolism, prevention, 255
Thromboxane B_2, 335
Thromboxane receptor antagonist, 97
Thymopsyche, 145
Tibolone, 510P
Tiracizine, 496P
Tolbutamide, 205
Tolerability, 145, 509P
Tolerance, 521P
TopFit, 117P
Torasemide, 478P
Training, 399
Tramadol, 325
Transdermal administration, 571
Tricyclic antidepressants, 93
Trigeminal nerve, 325, 445
Trilinolein, 457
Trimetazidine, 279

Undergraduate education, 129, 137
Undergraduate medical education, 474P, 514P
Urinary incontinence, 485P
Urine flow, 507P

Valproate, 559
Variability, 427, 563
Variance components, 427
Vasoconstriction, 473P
Vasopasm, 173
Veins, 441
Verapamil, 221, 460
Vigilance, 539
Viral infection, 187
Vital signs, 39

Warfarin enantiomers, 563
Warfarin metabolites, 563
Whole gut transit time, 488P

Xenobiotic exposure, 505P

Yohimbine, 93

ZD7288, 521P
Zidovudine, 7, 421, 495P, 480P